BACKGROUND: Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform. METHODS: Testing was performed on glioma samples as part of clinical care and analyzed up to 395 cancer-associated genes (including IDH1/2). The whole arm 1p19q codeletion status was predicted from the same assay using a custom research-use only algorithm, which was validated using 463 glioma samples with available fluorescence in-situ hybridization (FISH) data. For 519 patients with available outcomes data, progression-free and overall survival were assessed based on whole arm 1p19q codeletion status derived from sequencing data. RESULTS: Concordance between 1p19q status based on FISH and our algorithm was 96.7% (449/463) with a positive predictive value (PPV) of 100% and a positive percent agreement (PPA) of 91.0%. All discordant samples were positive for codeletion by FISH and harbored genomic alterations inconsistent with oligodendrogliomas. Median overall survival was 168 months for the IDH1/2 mutant, codeleted group, and 122 months for IDH1/2 mutant-only (hazard ratio (HR): 0.42; P < .05). CONCLUSIONS: 1p19q codeletion status derived from FoundationOne testing is highly concordant with FISH results. Genomic profiling may be a reliable substitute for traditional FISH testing while also providing IDH1/2 status.
BACKGROUND: Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform. METHODS: Testing was performed on glioma samples as part of clinical care and analyzed up to 395 cancer-associated genes (including IDH1/2). The whole arm 1p19q codeletion status was predicted from the same assay using a custom research-use only algorithm, which was validated using 463 glioma samples with available fluorescence in-situ hybridization (FISH) data. For 519 patients with available outcomes data, progression-free and overall survival were assessed based on whole arm 1p19q codeletion status derived from sequencing data. RESULTS: Concordance between 1p19q status based on FISH and our algorithm was 96.7% (449/463) with a positive predictive value (PPV) of 100% and a positive percent agreement (PPA) of 91.0%. All discordant samples were positive for codeletion by FISH and harbored genomic alterations inconsistent with oligodendrogliomas. Median overall survival was 168 months for the IDH1/2 mutant, codeleted group, and 122 months for IDH1/2 mutant-only (hazard ratio (HR): 0.42; P < .05). CONCLUSIONS: 1p19q codeletion status derived from FoundationOne testing is highly concordant with FISH results. Genomic profiling may be a reliable substitute for traditional FISH testing while also providing IDH1/2 status.
Authors: J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A Fenstermaker; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh Journal: J Natl Compr Canc Netw Date: 2017-11 Impact factor: 11.908
Authors: Caterina Giannini; Peter C Burger; Brian A Berkey; J Gregory Cairncross; Robert B Jenkins; Minesh Mehta; Walter J Curran; Ken Aldape Journal: Brain Pathol Date: 2008-03-26 Impact factor: 6.508
Authors: J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis Journal: J Natl Cancer Inst Date: 1998-10-07 Impact factor: 13.506
Authors: Lale Erdem-Eraslan; Lonneke A Gravendeel; Johan de Rooi; Paul H C Eilers; Ahmed Idbaih; Wim G M Spliet; Wilfred F A den Dunnen; Johannes L Teepen; Pieter Wesseling; Peter A E Sillevis Smitt; Johan M Kros; Thierry Gorlia; Martin J van den Bent; Pim J French Journal: J Clin Oncol Date: 2012-12-26 Impact factor: 44.544
Authors: M Labussière; A Idbaih; X-W Wang; Y Marie; B Boisselier; C Falet; S Paris; J Laffaire; C Carpentier; E Crinière; F Ducray; S El Hallani; K Mokhtari; K Hoang-Xuan; J-Y Delattre; M Sanson Journal: Neurology Date: 2010-04-28 Impact factor: 11.800
Authors: Artemis P Vogazianou; Raymond Chan; L Magnus Bäcklund; Danita M Pearson; Lu Liu; Cordelia F Langford; Simon G Gregory; V Peter Collins; Koichi Ichimura Journal: Neuro Oncol Date: 2010-02-17 Impact factor: 12.300
Authors: James X Sun; Yuting He; Eric Sanford; Meagan Montesion; Garrett M Frampton; Stéphane Vignot; Jean-Charles Soria; Jeffrey S Ross; Vincent A Miller; Phil J Stephens; Doron Lipson; Roman Yelensky Journal: PLoS Comput Biol Date: 2018-02-07 Impact factor: 4.475
Authors: Fan Zheng; Marcus R Kelly; Dana J Ramms; Marissa L Heintschel; Kai Tao; Beril Tutuncuoglu; John J Lee; Keiichiro Ono; Helene Foussard; Michael Chen; Kari A Herrington; Erica Silva; Sophie N Liu; Jing Chen; Christopher Churas; Nicholas Wilson; Anton Kratz; Rudolf T Pillich; Devin N Patel; Jisoo Park; Brent Kuenzi; Michael K Yu; Katherine Licon; Dexter Pratt; Jason F Kreisberg; Minkyu Kim; Danielle L Swaney; Xiaolin Nan; Stephanie I Fraley; J Silvio Gutkind; Nevan J Krogan; Trey Ideker Journal: Science Date: 2021-10-01 Impact factor: 63.714